News for Immunome, Inc. (IMNM)

[url="]Immunome,[/url] Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann

[url="]Immunome,[/url] Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann

By the end of March 31, 2025, Immunome (IMNM) reported a total of $317.3 million in cash, cash equivalents, and marketable securities. This figure reflects the

Immunome (IMNM) delivered earnings and revenue surprises of 21.21% and 28.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Revenue: Achieved $2.93 million, significantly surpassing the estimated $0.29 million.Net Loss: Reported a net loss of $41.6 million, an improvement from the $

Immunome (IMNM) reported a net loss of $41.6 million for Q1 2025, with cash and equivalents totaling $317.3 million as of March 31, 2025. The company is

Immunome (IMNM) is currently trading at a substantial discount, according to research by Piper Sandler. This assessment follows the announcement of a definitive

Immunome's strong financial position supports ongoing clinical development and potential market entry for key assets. See why I rate IMNM stock a buy.

Bitcoin breaks below $75,000 as crypto’s Trump rally fades, tariff turmoil. Tech bull Dan Ives slashes PT for Tesla, Apple over Trump's 'tariff armageddon.' Saudi Arabia slashes oil price.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that I

Immunome, Inc. (the ”œCompany”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The ...

In the opening 90 minutes of the evening session, U.S. stock futures are up marginally – S&P500 is up 0.1% while Nasdaq 100 is up 0.2%. Earlier on Tuesday, Consumer Discretionary and Communications Services were the best performing sectors in the S&P500 – Google (GOOGL), Meta (META), and Netflix (NFLX) had over 1% gains among the mega-caps – while defensively-oriented Healthcare and Utilities underperformed. Investors have also shrugged the disappointing Consumer Confidence data with sentiment t

**media[577745]**

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

[url="]Immunome,[/url] Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann

Immunome (IMNM) delivered earnings and revenue surprises of -23.53% and 10.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Discover Immunome's FY earnings update: GAAP EPS of -$5.00 and $9.04M revenue, down 35.5% YoY.

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that t